3
Clinical Trials associated with SPH3348SPH3348 Tablets in a Single-center, Randomized, Open-label, Single-dose, Two-period, Two-sequence Crossover Design Food Effect Study in Healthy Chinese Subjects
The goal of this clinical trial is to evaluate the pharmacokinetic (PK) characteristics of single oral doses of SPH3348 tablets in healthy subjects under fasting and fed conditions, as well as the impact of food on PK.
Phase I Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors with C-Met Abnormalities
This is a phase 1 clinical trial of SPH3348 tablets, a c-Met inhibitor, in patients with advanced solid tumors with c-Met abnormalities. A modified 3 + 3 design was adopted in patients with advanced solid tumors with c-Met abnormalities, with a total of 6 dose groups, in which accelerated dose escalation was adopted for the lowest dose group, and 3 + 3 dose escalation was adopted from the second dose group. The primary objective was to evaluate the safety and tolerability of SPH3348 tablets in patients with advanced solid tumors with c-Met abnormalities.
SPH3348片单药及联用奥希替尼治疗中国c-Met异常的晚期实体瘤患者的I期临床试验
[Translation] Phase I clinical trial of SPH3348 tablets alone and in combination with osimertinib in Chinese patients with advanced solid tumors with c-Met abnormalities
1.评价SPH3348片在c-Met异常的晚期实体瘤患者中的安全性和耐受性。 2.评估SPH3348片联用奥希替尼在EGFR突变、EGFR-TKI(1~3代)治疗耐药后,c-Met异常的局部晚期或转移性NSCLC患者中的安全性及耐受性。
[Translation] 1. To evaluate the safety and tolerability of SPH3348 tablets in patients with advanced solid tumors and c-Met abnormalities. 2. To evaluate the safety and tolerability of SPH3348 tablets combined with osimertinib in patients with locally advanced or metastatic NSCLC and c-Met abnormalities after EGFR mutations, resistance to EGFR-TKI (1st to 3rd generation) treatment.
100 Clinical Results associated with SPH3348
100 Translational Medicine associated with SPH3348
100 Patents (Medical) associated with SPH3348
100 Deals associated with SPH3348